TOP > 外国特許検索 > NUCLEOSIDE DERIVATIVE AND USE THEREOF

NUCLEOSIDE DERIVATIVE AND USE THEREOF コモンズ

外国特許コード F190009847
整理番号 (GI-H29-20)
掲載日 2019年7月25日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2018JP040544
国際公開番号 WO 2019088179
国際出願日 平成30年10月31日(2018.10.31)
国際公開日 令和元年5月9日(2019.5.9)
優先権データ
  • 特願2017-211339 (2017.10.31) JP
発明の名称 (英語) NUCLEOSIDE DERIVATIVE AND USE THEREOF コモンズ
発明の概要(英語) Provided are: a nucleoside that is more suitable for practical use such as an RNA medicine or the like; and the use of the nucleoside. For this purpose, provided is a nucleoside derivative represented by formula (1) or (2) or a salt thereof. [Chem. 16] (In formula (1), R1 represents a hydrogen atom, a hydroxy group, a hydroxy group in which a hydrogen atom is substituted with an alkyl group or an alkenyl group, or a protected group, and in formula (2), X represents a halogen atom. In formula (1) and formula (2), R2 and R3 may be the same or different and each represent a hydrogen atom, a protecting group for a hydroxy group, a phosphate group, a protected phosphate group, or -P(=O)nR5R6 (n represents 0 or 1, R5 and R6 may be the same or different and each represent a hydrogen atom, a hydroxy group, a protected hydroxy group, a mercapto group, a protected mercapto group, a lower alkoxy group, a cyano lower alkoxy group, an amino group, or a substituted amino group. Note that when n is 1, R5 and R6 would not simultaneously be a hydrogen atom.), each R4 represents NHR7 having a linking group (R7 represents a hydrogen atom, an alkyl group, an alkenyl group, or a protecting group for amino group), an azide group, an amidino group, or a guanidino group, and B represents one of a purin-9-yl group, a 2-oxo-pyrimidin-1-yl group, a substituted purin-9-yl group, or a substituted 2-oxo-pyrimidin-1-yl group.)
従来技術、競合技術の概要(英語) BACKGROUND ART
Including cancer, genetic mutations or gene expression caused by disease or abnormality associated with the known multiple. Gene to inhibit expression of RNA of the medicament such as siRNA, is useful for such a disease, said to have excellent pharmaceutical potential.
On the other hand, such as siRNA is, the cell membrane is difficult, prone to degradation by nucleases problem. For this reason, heretofore, such as intracellular delivery of siRNA for LNP or attempted use of the carrier, various chemical modifications for nucleosides have been tried (Non-Patent Document 1-4).
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • YAMASA CORPORATION
  • GIFU UNIVERSITY
  • 発明者(英語)
  • UENO Yoshihito
  • MAEDA Yusuke
  • KAJINO Ryohei
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
岐阜大学産官学連携推進本部では、岐阜大学における知的財産の創出・管理・活用のマネジメントをしています。上記の特許・技術に関心のある方は、下記問い合わせ先に整理番号とともにご相談下さい。

PAGE TOP

close
close
close
close
close
close